Interleukin-12: Opportunities for the treatment of bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 147-155

  Clinton, Steven K ^a   Canto, Eduardo ^b   O'Donnell, Michael A ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033964307     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70242-1     Document Type: Article

References (74)

1. F. Altare A. Durandy D. Lammas Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency Science 280 1998 1432 521435
2. M.B. Atkins M.J. Robertson M. Gordon Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 3 1997 409 417
3. J.L. Bramson M. Hitt C.L. Addison Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum Gene Ther 7 1996 1995 2002
4. A.G. Bree F.J. Schlerman M.D. Kaviani Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates Biochem Biophys Res Commun 204 1994 1150 1157
5. M.J. Brunda L. Luistro R.R. Warrier Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 178 1993 1223 1230
6. B.D. Car V.M. Eng J.M. Lipman The toxicology of interleukin-12: A review Toxicol Pathol 27 1999 58 63
7. F. Cavallo E. Di Carlo M. Butera Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12 Cancer Res 59 1999 414 421
8. L. Chen D. Chen E. Block Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer J Immunol 159 1997 351 359
9. J. Cohen IL-12 deaths: Explanation and a puzzle Science 270 1995 908
10. C.M. Coughlin K.E. Salhany M. Wysocka Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis J Clin Invest 101 1998 1441 1452
11. A. D'Andrea M. Rengaraju N.M. Valiante Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells J Exp Med 176 1992 1387 1398
12. R. de Jong F. Altare I.A. Haagen Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients Science 280 1998 1435 1438
13. B.B. Desai P.M. Quinn A.G. Wolitzky IL-12 receptor. II. Distribution and regulation of receptor expression J Immunol 148 1992 3125 3132
14. S. Dias R. Boyd F. Balkwill IL-12 regulates VEGF and MMPs in a murine breast cancer model Int J Cancer 78 1998 361 365
15. M.C. Filion P. Lepicier A. Morales Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells Br J Cancer 79 1999 229 235
16. M.K. Gately Interleukin-12: A recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors Cancer Invest 11 1993 500 506
17. M.K. Gately B.B. Desai A.G. Wolitzky Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor) J Immunol 147 1991 874 882
18. M.K. Gately L.M. Renzetti J. Magram The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses Annu Rev Immunol 16 1998 495 521
19. D.P. Gearing D. Cosman Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor Cell 66 1991 9 10
20. S. Gillessen D. Carvajal P. Ling Mouse interleukin-12 (IL-12) p40 homodimer: A potent IL-12 antagonist Eur J Immunol 25 1995 200 206
21. J. Golab R. Zagozdzon Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review) International Journal of Molecular Medicine 3 1999 537 544
22. U. Gubler A.O. Chua D.S. Schoenhaut Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor Proc Natl Acad Sci USA 88 1991 4143 4147
23. U. Gubler D.H. Presky Molecular biology of interleukin-12 receptors Ann NY Acad Sci 795 1996 36 40
24. W. Hashimoto T. Osaki H. Okamura Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively J Immunol 163 1999 583 589
25. H. Herr R.A. Badalament D.A. Amato Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression J Urol 141 1989 22 29
26. H.W. Herr V.P. Laudone R.A. Badalament BCG therapy alters progression of superficial bladder cancer J Clin Oncol 6 1988 1450
27. H.W. Herr C.M. Pinsky W.F. Whitmore Long-term effect of bacillus Calmette-Guerin on flat carcinoma in situ of the bladder J Urol 135 1986 265 271
28. H.W. Herr D.M. Schwalb Z.-F. Zhang Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404 1408
29. S.E. Hunter K.E. Waldburger D.K. Thibodeaux Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: Cellular and cytokine-mediated effector mechanisms Eur J Immunol 27 1997 3438 3446
30. A.M. Jackson A.V. Ivshina O. Senko Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: Statistically weighted syndrome analysis J Urol 159 1998 1054 1063
31. K. Kato O. Shimozato K. Hoshi Local production of the p40 subunit of interleukin-12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection Proc Natl Acad Sci USA 93 1996 9085 9089
32. M. Kobayashi L. Fitz M. Ryan Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes J Exp Med 170 1989 827 846
33. T. Kodama K. Takeda O. Shimozato Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12 Eur J Immunol 29 1999 1390 1396
34. J.P. Leonard M.L. Sherman G.L. Fisher Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-gamma production Blood 90 1997 2541 2548
35. F.H. Lieu T.S. Hawley A.Z. Fong Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy Cancer Gene Ther 4 1997 167 175
36. P. Ling M.K. Gately U. Gubler Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity J Immunol 154 1995 116 127
37. P. Lissoni F. Rovelli S. Pittalis Interleukin-12 in early or advanced cancer patients Eur J Cancer 33 1997 1703 1705
38. P. Lissoni F. Rovelli M.R. Rivolta Acute endocrine effects of interleukin-12 in cancer patients J Biol Regul Homeost Agents 11 1997 154 156
39. L.N. Lode R. Xiang S.R. Duncan Tumor-targeted IL-2 amplifies T cell–mediated immune response induced by gene therapy with single-chain IL-12 Proc Natl Acad Sci USA 96 1999 8591 8596
40. M.T. Lotze B. Hellerstedt L. Stolinski The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy Cancer J Sci Am 1 suppl 1997 109 114
41. S.E. Macatonia N.A. Hosken M. Litton Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells J Immunol 154 1995 5071 5079
42. F. Mattner S. Fischer S. Guckes The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer Eur J Immunol 23 1993 2202 2208
43. J.B. Meko J.H. Yim K. Tsung High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin-12 Cancer Res 55 1995 4765 4770
44. P. Mendez-Samperio H.E. Ayala-Verdin A. Trejo-Echeverria Interleukin-12 regulates the production of bacille Calmette-Guerin–induced interferon-gamma from human cells in a CD40-dependent manner Scand J Immunol 50 1999 61 67
45. D.M. Merberg S.F. Wolf S.C. Clark Sequence similarity between NKSF and the IL-6/G-CSF family Immunol Today 13 1992 77 78
46. C.L. Nastala H.D. Edington T.G. McKinney IL-12 administration induces tumor regression in association with IFN-γ production J Immunol 153 1994 1697 1706
47. Y. Nishioka M. Hirao P.D. Robbins Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 Cancer Res 15 1999 4035 4041
48. Y. Noguchi E.C. Richards Y.-T. Chen Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma Proc Natl Acad Sci USA 92 1995 2219 2223
49. M.A. O'Donnell W.C. DeWolf Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer Adv Urol Oncol 4 1995 189 202
50. M.A. O'Donnell Y. Luo X. Chen Role of IL-12 in the induction and potentiation of IFNγ in response to BCG J Immunol 163 1999 4246 4252
51. J.R. Piccotti K. Li S.Y. Chan Interleukin-12 (IL-12)–driven alloimmune responses in vitro and in vivo: Requirement for beta subunit of the IL-12 receptor Transplantation 67 1999 1453 1460
52. D.P. Poppas C.P. Pavlovich J. Folkman Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10 Urology 52 1998 268 275 discussion 275–276
53. D.H. Presky H. Yang L.J. Minetti A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits Proc Natl Acad Sci USA 93 1996 14002 14007
54. A.L. Rakhmilevich J.G. Timmins K. Janssen Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 protein therapy J Immunother 22 1999 135 144
55. M.J. Robertson C. Cameron M.B. Atkins Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer Clin Cancer Res 5 1999 9 16
56. M.J. Robertson J. Ritz Interleukin 12: Basic biology and potential applications in cancer treatment The Oncologist 1 1996 88 97
57. U.M. Sarmiento J.H. Riley P.A. Knaack Biologic effects of recombinant human interleukin-12 in squirrel monkeys ( Sciureus saimiri ) Lab Invest 71 1994 862 873
58. D.S. Schoenhaut A.O. Chua A.G. Wolitzky Cloning and expression of murine IL-12 J Immunol 148 1992 3433 3440
59. A. Snijders C.M. Hilkens T. Krann Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit J Immunolo 156 1996 1207 1212
60. A.S. Stern J.D. Hulmes Y.E. Pan Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells Proc Natl Acad Sci USA 87 1990 6808 6812
61. H. Tahara L. Zitvogel W.J. Storkus Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector J Immunol 154 1995 6466 6474
62. B.A. Teicher G. Ara D. Buxton Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma Clin Cancer Res 3 1997 1661 1667
63. B.A. Teicher G. Ara D. Buxton Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma Radiat Oncol Invest 6 1998 71 80
64. G. Trinchieri Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity Annu Rev Immunol 13 1995 251 276
65. K. Tsung J.B. Meko Y.L. Tsung Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12 J Immunol 160 1998 1369 1377
66. J. Ulchaker J. Panuto P. Rayman Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12 J Immunother 22 1999 71 79
67. E.E. Voest B.M. Kenyon M.S. O'Reilly Inhibition of angiogenesis in vivo by interleukin 12 J Natl Cancer Inst 87 1995 581 586
68. X. Wang V.L. Wilkinson F.J. Podlaski Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits Eur J Immunol 29 1999 2007 2013
69. Weiss G, O'Donnell M, Conlon K, et al. Phase I trial of the intravesical administration of recombinant human interleukin-12 (rhIL-12) for superficial transitional cell bladder carcinoma [abstract 1284] In Program Proceedings of the American Society of Clinical Oncology 1999, p 334, Atlanta, Georgia
70. S.F. Wolf P.A. Temple M. Kobayashi Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells J Immunol 146 1991 3074 3081
71. C.Y. Wu R.R. Warrier D.M. Carvajal Biological function and distribution of human interleukin-12 receptor beta chain Eur J Immunol 26 1996 345 350
72. K. Yamanaka I. Hara H. Nagai Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model Cancer Immunol Immunother 48 1999 297 302
73. M. Zhang J. Gong D. Presky Expression of the IL-12 receptor beta 1 and beta 2 subunits in human tuberculosis J Immunol 162 1999 2441 2447
74. L. Zitvogel H. Tahara Q. Cai Construction and characterization of retroviral vectors expressing biologically active human interleukin-12 Hum Gene Ther 5 1994 1493 1506